Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7913 and ONO-4538 with mFOLFIRINOX in Metastatic Pancreatic Cancer
NCT06532344Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magrolimab and nivolumab, sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse event at 30 days. Started Jul 2021; status: active, not recruiting.
02
Drugs
magrolimabnivolumab
Beyond the preview
Go deeper on NCT06532344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532344.